121 related articles for article (PubMed ID: 37857190)
1. ATM-AMPKα mediated LAG-3 expression suppresses T cell function in prostate cancer.
Zhang X; Chen H; Han J; Wang Z; Guo Y; Zhou Z; Luo R; Dai M; Ou W; Chen L; Shao L
Cell Immunol; 2023; 393-394():104773. PubMed ID: 37857190
[TBL] [Abstract][Full Text] [Related]
2. Elevated Expression of Hepatoma Up-Regulated Protein Inhibits γ-Irradiation-Induced Apoptosis of Prostate Cancer Cells.
Hassan M; El Khattouti A; Ejaeidi A; Ma T; Day WA; Espinoza I; Vijayakumar S; Gomez CR
J Cell Biochem; 2016 Jun; 117(6):1308-18. PubMed ID: 26505164
[TBL] [Abstract][Full Text] [Related]
3. Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals.
Xie H; Li C; Dang Q; Chang LS; Li L
Oncotarget; 2016 Jan; 7(2):1341-53. PubMed ID: 26625310
[TBL] [Abstract][Full Text] [Related]
4. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
5. Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.
Gulliver C; Hoffmann R; Baillie GS
Int J Biochem Cell Biol; 2022 Jun; 147():106230. PubMed ID: 35609768
[TBL] [Abstract][Full Text] [Related]
6. ATM‑JAK‑PD‑L1 signaling pathway inhibition decreases EMT and metastasis of androgen‑independent prostate cancer.
Zhang L; Xu LJ; Zhu J; Li J; Xue BX; Gao J; Sun CY; Zang YC; Zhou YB; Yang DR; Shan YX
Mol Med Rep; 2018 May; 17(5):7045-7054. PubMed ID: 29568923
[TBL] [Abstract][Full Text] [Related]
7. ATM Inhibition Potentiates Death of Androgen Receptor-inactivated Prostate Cancer Cells with Telomere Dysfunction.
Reddy V; Wu M; Ciavattone N; McKenty N; Menon M; Barrack ER; Reddy GP; Kim SH
J Biol Chem; 2015 Oct; 290(42):25522-33. PubMed ID: 26336104
[TBL] [Abstract][Full Text] [Related]
8. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
[TBL] [Abstract][Full Text] [Related]
9. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
[TBL] [Abstract][Full Text] [Related]
10. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2.
Chen X; Chen F; Ren Y; Weng G; Xu L; Xue X; Keng PC; Lee SO; Chen Y
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1471-1484. PubMed ID: 31020420
[TBL] [Abstract][Full Text] [Related]
11. N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway.
Yin Y; Xu L; Chang Y; Zeng T; Chen X; Wang A; Groth J; Foo WC; Liang C; Hu H; Huang J
Mol Cancer; 2019 Jan; 18(1):11. PubMed ID: 30657058
[TBL] [Abstract][Full Text] [Related]
12. ATM influences the efficiency of TCRβ rearrangement, subsequent TCRβ-dependent T cell development, and generation of the pre-selection TCRβ CDR3 repertoire.
Hathcock KS; Bowen S; Livak F; Hodes RJ
PLoS One; 2013; 8(4):e62188. PubMed ID: 23626787
[TBL] [Abstract][Full Text] [Related]
13. Early Growth Response Gene 2-Expressing CD4
Okamura T; Yamamoto K; Fujio K
Front Immunol; 2018; 9():340. PubMed ID: 29535721
[TBL] [Abstract][Full Text] [Related]
14. Functional activation of ATM by the prostate cancer suppressor NKX3.1.
Bowen C; Ju JH; Lee JH; Paull TT; Gelmann EP
Cell Rep; 2013 Aug; 4(3):516-29. PubMed ID: 23890999
[TBL] [Abstract][Full Text] [Related]
15. Egr2 and Egr3 in regulatory T cells cooperatively control systemic autoimmunity through Ltbp3-mediated TGF-β3 production.
Morita K; Okamura T; Inoue M; Komai T; Teruya S; Iwasaki Y; Sumitomo S; Shoda H; Yamamoto K; Fujio K
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):E8131-E8140. PubMed ID: 27911796
[TBL] [Abstract][Full Text] [Related]
16. Positive regulation of ataxia-telangiectasia-mutated protein (ATM) by E2F transcription Factor 1 (E2F-1) in cisplatin-resistant nasopharyngeal carcinoma cells.
Zhou ZY; Yang JY; Shao CZ; Luo F; Du W
World J Surg Oncol; 2022 Mar; 20(1):88. PubMed ID: 35303867
[TBL] [Abstract][Full Text] [Related]
17. TR4 nuclear receptor functions as a tumor suppressor for prostate tumorigenesis via modulation of DNA damage/repair system.
Lin SJ; Lee SO; Lee YF; Miyamoto H; Yang DR; Li G; Chang C
Carcinogenesis; 2014 Jun; 35(6):1399-406. PubMed ID: 24583925
[TBL] [Abstract][Full Text] [Related]
18. Analysis of ataxia-telangiectasia mutated (ATM)- and Nijmegen breakage syndrome (NBS)-regulated gene expression patterns.
Jang ER; Lee JH; Lim DS; Lee JS
J Cancer Res Clin Oncol; 2004 Apr; 130(4):225-34. PubMed ID: 14745549
[TBL] [Abstract][Full Text] [Related]
19. Molecular and Functional Characterization of a Cohort of Spanish Patients with Ataxia-Telangiectasia.
Carranza D; Vega AK; Torres-Rusillo S; Montero E; Martinez LJ; Santamaría M; Santos JL; Molina IJ
Neuromolecular Med; 2017 Mar; 19(1):161-174. PubMed ID: 27664052
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic Stem Cell Transplantation Restores Naïve T-Cell Populations in
Duecker R; Baer PC; Buecker A; Huenecke S; Pfeffermann LM; Modlich U; Bakhtiar S; Bader P; Zielen S; Schubert R
Front Immunol; 2019; 10():2785. PubMed ID: 31849966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
